M&T Bank Corporation vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? M&T Bank Corporation trades at $217.57 (market cap $31.42B), while Royalty Pharma plc Class A Ordinary Shares trades at $56.96 (market cap $25.27B). The key difference: M&T Bank Corporation is the larger of the two by market cap, and M&T Bank Corporation pays the higher dividend (2.76%). Which is the better fit depends on your goals — on Pluang, investors hold M&T Bank Corporation for 100 Days and Royalty Pharma plc Class A Ordinary Shares for 1 Days on average.
| MTB | RPRX | |
|---|---|---|
Market Cap | $31.42B | $25.27B |
Volume | 1,438,219 | 3,671,183 |
Sector | Financials | Health |
52-Week High | $254.09 | $63.96 |
52-Week Low | $178.63 | $35.44 |
Typical Hold Time | 100 Days | 1 Days |
Enterprise Value | $47.77B | $32.50B |
Dividend Yield | 2.76% | 1.66% |
Signals from Pluang's Aura AI — not financial advice
M&T Bank Corporation (MTB) trades at $217.23, up 0.29% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with P/E of 11.52, net margin of 30.85%, and consistent dividend payments. Recent news highlights branch expansion and AI investments driving loan growth, while analyst consensus remains cautiously optimistic with a $258.92 price target.
MTB presents a compelling value opportunity with attractive valuation metrics and solid profitability, though technical indicators suggest near-term pressure. The bank's strategic investments in technology and expanding fee businesses support long-term growth, but investors should monitor interest rate sensitivity and competitive banking sector dynamics.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →